Peptadermsp. z o.o. in liquidation
Research and experimental development on biotechnology
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2009-03-12
Share capital
60,600.00 PLN
Registered address
ul. Gen. Józefa Zajączka 11/90, 01-510 Warszawa, Poland
Electronic delivery address
AE:PL-87893-23279-WSJHU-17
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 5 of 6 financial statements were filed late (the longest delay 126 days for 2023).
- 2025not filed
- 202403/09/2025
- 202318/11/2024
- 202203/10/2023
- 202114/10/2022
- 202012/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Voivodeship · Mazowieckie137,773 / 142,048
Top 97%
Country · Poland484,274 / 495,935
Top 98%
Results vs industry
Revenue
This companyUSD 0.37MedianUSD 55.66kAverageUSD 2.70m
Net profit
This companyUSD -483.65kMedianUSD -1.27kAverageUSD -92.16k
Operating costs
This companyUSD 7.29kMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 3.96kMedianUSD 133.19kAverageUSD 3.03m
Industry
Trademarks
Peptaderm holds 1 active trademark registered with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2010.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| PEPTADERM(word) | Z.364700 | 5 | Protected | Jan 4, 2030 | |
| PEPTADERM | Z.438389 | 3, 5, 42, 44 | Expired | – |
| Mark | Protected until | |
|---|---|---|
| PEPTADERM(word) | Jan 4, 2030 | |
| PEPTADERM | – |
Authorized Representatives
Anna Elżbieta Aranowska-Bablokage 46 – Liquidator
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 920 | $12,425.72 | 75.9076% | |
| 146 | $1,971.91 | 12.0462% | |
Others | 146 | $1,971.91 | 12.0462% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 27, 2024 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Omnisepticasp. z o.o. | $3,475.29 | omniseptica.com | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-07-23 | Address change (Ul. Stefana Batorego 18/108, 02-591, Warszawa → Ul. Gen. Józefa Zajączka 11/90, 01-510, Warszawa) | |
| 2024-02-22 | Name change (Peptaderm → Peptaderm Spółka Z Ograniczoną Odpowiedzialnością W Likwidacji) | |
| 2023-12-29 | Liquidation opened | |
| 2023-06-02 | Address change (Ul. Gen. Józefa Zajączka 11/14, 01-510, Warszawa → Ul. Stefana Batorego 18/108, 02-591, Warszawa) | |
| 2020-02-19 | Address change (Ul. Zygmunta Słomińskiego 15/509, 00-195, Warszawa → Ul. Gen. Józefa Zajączka 11/14, 01-510, Warszawa) |
FAQ
The main business activity of Peptaderm focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on March 12, 2009.
The headquarters is located at: ul. Gen. Józefa Zajączka 11, 01-510 Warszawa.
The share capital of the company is PLN 60,600 (approx. $16,370).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $0, representing a decrease of 100.0% compared to 2023.
No, the company recorded a net loss of $483,647 in 2024. For comparison, in 2023 the loss was $2,619, representing a multi-fold increase in the loss compared to 2023.
The largest operating cost category falls under external services. This category amounted to $7,285 in 2024, representing 100% of all operating expenses.
Last updated: 2026-10-04